LesleyNewman
2021-11-08

Longs, disappointing we missed 3Q, but MRNA is oversold on the news. This is only 3d time MRNA reported since launching 1st commercial product. Here's the reality:

- 3Q $5B revenue & $7 EPS is still increasing tread over last 2Qs.

- 4Q will continue upward tread.

- MRNA has $17B in Advance Purchase Orders for 2022.

- MRNA reported record Cash on Hand.

- MRNA grabbed 40 institutions last week. We now have 1414 (+97 since 1 OCT).

GL LONGS, disappointing dip, but as an investor, I'm accumulating next week...

$Moderna, Inc.(MRNA)$$Moderna, Inc.(MRNA)$

免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法
2